Phoenix, Arizona, September 15, 2026
Castle Biosciences has announced findings from a new decision-modeling study showing that its TissueCypher Barrett’s Esophagus test can significantly improve risk-aligned management strategies for patients with Barrett’s esophagus. The study evaluated how incorporating TissueCypher into clinical decision-making could influence surveillance and treatment strategies while potentially improving the identification of patients at higher risk of disease progression. The findings add to the growing body of evidence supporting the use of molecular diagnostic technology and personalized risk assessment in gastrointestinal disease management. By providing additional biological information beyond conventional clinical and histopathologic assessment, TissueCypher is designed to help physicians better distinguish patients who may require closer monitoring from those who may be appropriately managed with less intensive surveillance.
TissueCypher Supports Risk-Aligned Patient Management
Barrett’s esophagus is a condition in which the normal lining of the esophagus changes, generally as a consequence of chronic gastroesophageal reflux. Although many patients with Barrett’s esophagus do not develop cancer, the condition is associated with an increased risk of progression to high-grade dysplasia and esophageal adenocarcinoma. Determining which patients are most likely to progress remains a significant challenge for clinicians. TissueCypher is designed to provide additional information about a patient’s risk of progression by analyzing biomarkers within esophageal tissue. The test combines multiple molecular and morphologic features to generate a risk classification that can complement traditional pathology evaluation. The objective is to provide physicians with a more individualized assessment that may support decisions about surveillance and treatment. The new decision-modeling study examined how using TissueCypher could affect management recommendations compared with conventional approaches. According to Castle Biosciences, the analysis demonstrated that incorporating the test could produce more risk-aligned clinical management, helping direct greater resources toward patients with higher progression risk while potentially reducing unnecessary interventions and surveillance in lower-risk individuals.
Decision Modeling Highlights Value of Molecular Diagnostics
The study is important because the management of Barrett’s esophagus often requires balancing two competing concerns: identifying patients who require timely intervention while avoiding unnecessary procedures in individuals whose disease is unlikely to progress. Conventional approaches may not always provide sufficient biological information to distinguish these risk groups. By incorporating TissueCypher into the decision pathway, clinicians may gain access to additional patient-specific risk information that can complement endoscopic and histopathological findings. Decision modeling allows researchers to examine the potential consequences of incorporating a diagnostic test into real-world clinical management, including potential changes in surveillance intensity and treatment decisions. Castle Biosciences reported that the model showed significant improvements in risk-aligned management when TissueCypher results were incorporated. The findings support the concept that molecular diagnostics can contribute to more personalized healthcare by moving clinical decisions beyond a one-size-fits-all approach. However, decision-modeling studies differ from prospective clinical outcome trials. Modeling evaluates expected outcomes based on available evidence and assumptions, meaning the findings should be interpreted as evidence supporting potential clinical utility rather than proof that every patient will experience improved outcomes.
Advertisement
Advancing Personalized Barrett’s Esophagus Care
The findings add to Castle Biosciences’ broader focus on developing molecular diagnostic tests designed to provide clinically actionable information. The company develops tests that use molecular and genomic information to help physicians make more informed decisions in oncology and other areas of medicine. For patients with Barrett’s esophagus, improved risk stratification could be particularly valuable because progression to esophageal cancer is relatively uncommon among many individuals with the condition. A diagnostic tool capable of identifying patients at elevated risk could potentially help physicians focus surveillance and therapeutic resources where they are most needed. The growing adoption of precision medicine is driving increased interest in diagnostic technologies capable of identifying biological differences between patients who may otherwise appear clinically similar. Tissue-based molecular tests such as TissueCypher represent one approach to achieving more individualized risk assessment. The new study therefore provides an important perspective on how diagnostic information can potentially influence healthcare decision-making. Rather than simply identifying disease, advanced molecular diagnostics increasingly aim to provide information about disease behavior and future risk, allowing clinicians to tailor management according to individual patient characteristics. For cGxP.wire readers, Castle Biosciences’ announcement represents a significant development in medical diagnostics, pathology and personalized medicine. The TissueCypher decision-modeling findings suggest that molecular risk assessment could play an increasingly important role in the management of Barrett’s esophagus. Continued clinical validation and real-world implementation will help determine the extent to which such testing can improve patient care and optimize the use of healthcare resources.
Source: Castle Biosciences press release
